Neutrophil-lymphocyte ratio is a prognosticmarker in patients with locally advanced (stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapy

Katherine A. Scilla, Søren M. Bentzen, Vincent K. Lam, Pranshu Mohindra, Elizabeth M. Nichols, Melissa A. Vyfhuis, Neha Bhooshan, Steven J. Feigenberg, Martin J. Edelman, Josephine L. Feliciano

Research output: Contribution to journalArticlepeer-review

Abstract

Background. Neutrophil-lymphocyte ratio (NLR) is a measure of systemic inflammation that appears prognostic in localized and advanced non-small cell lung cancer (NSCLC). Increased systemic inflammation portends a poorer prognosis in cancer patients. We hypothesized that low NLR at diagnosis is associated with improved overall survival (OS) in locally advanced NSCLC (LANSCLC) patients. Patients and Methods. Records from 276 patients with stage IIIA and IIIB NSCLC treated with definitive chemoradiation with or without surgery between 2000 and 2010 with adequate data were retrospectively reviewed. Baseline demographic data and pretreatment peripheral blood absolute neutrophil and lymphocyte counts were collected. Patients were grouped into quartiles based on NLR. OS was estimated using the Kaplan- Meiermethod.The log-rank test was used to comparemortality between groups. A linear test-for-trend was used for the NLR quartile groups. The Cox proportional hazards model was used for multivariable analysis. Results. The NLR was prognostic for OS (p < .0001).Median survival in months (95% confidence interval) for the first, second, third, and fourth quartile groups of the population distribution of NLR were 27 (19-36), 28 (22-34), 22 (12-31), and 10 (8-12), respectively. NLR remained prognostic for OS after adjusting for race, sex, stage, performance status, and chemoradiotherapy approach (p = .004). Conclusion. To our knowledge, our series is the largest to demonstrate that baseline NLR is a significant prognostic indicator in LANSCLC patients who received definitive chemoradiation with or without surgery. As an indicator of inflammatory response, it should be explored as a potential predictive marker in the context of immunotherapy and radiation therapy.

Original languageEnglish (US)
Pages (from-to)737-742
Number of pages6
JournalOncologist
Volume22
Issue number6
DOIs
StatePublished - Jun 2017

Keywords

  • Locally advanced
  • Neutrophil-lymphocyte ratio
  • Non-small cell lung cancer
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Neutrophil-lymphocyte ratio is a prognosticmarker in patients with locally advanced (stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapy'. Together they form a unique fingerprint.

Cite this